Omeros (OMER) to Release Earnings on Thursday

Omeros (NASDAQ:OMER) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Omeros to post earnings of ($0.27) per share and revenue of $12.6910 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to analyst estimates of $4.19 million. On average, analysts expect Omeros to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Omeros Stock Performance

Shares of OMER stock opened at $13.62 on Tuesday. The stock’s fifty day moving average is $10.46 and its 200-day moving average is $11.44. The stock has a market capitalization of $985.82 million, a PE ratio of 19.46 and a beta of 2.54. Omeros has a 52 week low of $3.89 and a 52 week high of $17.65.

Insider Buying and Selling

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the sale, the director directly owned 35,067 shares in the company, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.50% of the company’s stock.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in OMER. State of Wyoming acquired a new stake in Omeros during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Omeros in the fourth quarter valued at about $33,000. Arax Advisory Partners increased its holdings in shares of Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 1,894 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Omeros by 34.6% in the fourth quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 1,938 shares in the last quarter. Finally, Abel Hall LLC acquired a new stake in shares of Omeros during the fourth quarter worth about $176,000. Institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on OMER shares. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen cut shares of Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Tuesday, April 21st. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.